search
Back to results

A Study With GLPG1972 in Osteoarthritis Subjects

Primary Purpose

Osteoarthritis

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
GLPG1972 cohort 1
GLPG1972 cohort 2
GLPG1972 cohort 3
Placebo
Sponsored by
Galapagos NV
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoarthritis

Eligibility Criteria

50 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male or female subjects of non-childbearing potential, 50-75 years of age on the date of signing the Informed Consent Form (ICF), inclusive extremes.
  2. Diagnosis of OA (knee and/or hip) made by their physician based on symptoms, clinical signs and documented historical imaging evidence.
  3. A body mass index (BMI) between 18.0 and 34.9 kg/m2, inclusive extremes.
  4. Judged to be in age-appropriate good health by the investigator based upon the results of a medical history, physical examination, vital signs and 12-lead ECG, and fasting clinical laboratory profile.
  5. Subjects with a stable chronic illness at least 3 months will be accepted subject to the investigator's judgment.

Exclusion Criteria:

  1. Administration of intraarticular glucocorticoid injections or hyaluronan injections in the last 3 months prior to study screening.
  2. Subjects who underwent or are on a waiting list for total hip or knee replacement and any other surgery planned during the study (up to Day 50).
  3. Known hypersensitivity to study drug ingredients or a significant allergic reaction to any drug as determined by the investigator, such as anaphylaxis requiring hospitalization.
  4. Positive serology for HBsAg or HCV antibody or history of hepatitis from any cause with the exception of hepatitis A.
  5. History of or a current immunosuppressive condition.
  6. Clinically significant serious, per investigator's discretion, and/or unstable illness in the 3 months before screening
  7. Renal function with an estimated creatinine clearance < 60 mL/min based on the Cockcroft-Gault formula. Retesting is allowed once (see Section 5.2).
  8. Use of verapamil, diltiazem, amitriptyline, warfarin, acenocoumarol, phenobarbital and phenytoin, within 4 weeks before first study drug administration
  9. Consumption of herbal medications that are strong inhibitors and/or inducers of CYPs (e.g., St. John's Wort) and grapefruit/grapefruit products, Seville oranges, or any poppy seed, within 7 days prior to the first study drug administration.
  10. History of solid organ or hematopoietic cell transplantation.
  11. History of malignancy within the past 5 years.
  12. Clinically significant abnormalities detected on 12-lead ECG of either rhythm or conduction (e.g., QTcF ≥ 450 ms for males and QTcF ≥ 470 ms for females, or a known long QT syndrome).
  13. Significant blood loss (including blood donation [> 450 mL]), or transfusion of any blood product within 12 weeks prior to screening

Sites / Locations

  • Covance Daytona Beach

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

GLPG1972

Placebo

Arm Description

Outcomes

Primary Outcome Measures

Difference between GLPG1972 treated subjects and placebo subjects in the number of Adverse Events
To assess safety and tolerability of GLPG1972 in OA patients
Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal vital signs
To assess safety and tolerability of GLPG1972 in OA patients
Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal clinical laboratory evaluations
To assess safety and tolerability of GLPG1972 in OA patients
Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal physical examination
To assess safety and tolerability of GLPG1972 in OA patients
Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal ECG
To assess safety and tolerability of GLPG1972 in OA patients
Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal Holter assessment
To assess safety and tolerability of GLPG1972 in OA patients
The maximum observed plasma concentration of GLPG1972 (Cmax)
To assess PK of GLPG1972 in OA patients
The time (tmax) to reach Cmax of GLPG1972
To assess PK of GLPG1972 in OA patients
The plasma concentration of GLPG1972 24 after the last dose
To assess PK of GLPG1972 in OA patients
The area under the plasma concentration time curve from time 0 until the last quantifieble dose
To assess PK of GLPG1972 in OA patients

Secondary Outcome Measures

Percentage reduction of neo-epitope ARGS vs baseline
To assess PD of GLPE1972 in OA patients

Full Information

First Posted
October 11, 2017
Last Updated
November 21, 2017
Sponsor
Galapagos NV
search

1. Study Identification

Unique Protocol Identification Number
NCT03311009
Brief Title
A Study With GLPG1972 in Osteoarthritis Subjects
Official Title
Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Doses of GLPG1972 for 4 Weeks in Subjects With Osteoarthritis
Study Type
Interventional

2. Study Status

Record Verification Date
November 2017
Overall Recruitment Status
Completed
Study Start Date
May 15, 2017 (Actual)
Primary Completion Date
October 25, 2017 (Actual)
Study Completion Date
October 25, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Galapagos NV

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a randomized, double-blind, placebo-controlled, stratified, ascending dose, single center study, in three semi-sequential cohorts of 10 male and female subjects of nonchildbearing potential with Osteoarthritis (OA), administered GLPG1972 or placebo. Per cohort, 10 subjects will be randomized in a 4:1 allocation ratio to active treatment with GLPG1972 or matching placebo. In each cohort, OA subjects will be stratified for age (50- 64 years and 65-75 years) with a minimum of 2 of each sex per age group.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
GLPG1972
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
GLPG1972 cohort 1
Intervention Description
GLPG1972 dose 1 provided as oral tablets q.d.
Intervention Type
Drug
Intervention Name(s)
GLPG1972 cohort 2
Intervention Description
GLPG1972 dose 2 provided as oral tablets q.d.
Intervention Type
Drug
Intervention Name(s)
GLPG1972 cohort 3
Intervention Description
GLPG1972 dose 3 provided as oral tablets q.d.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Matching placebo provided as oral tablets q.d.
Primary Outcome Measure Information:
Title
Difference between GLPG1972 treated subjects and placebo subjects in the number of Adverse Events
Description
To assess safety and tolerability of GLPG1972 in OA patients
Time Frame
From screening until the final follow up visit (day 50)
Title
Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal vital signs
Description
To assess safety and tolerability of GLPG1972 in OA patients
Time Frame
From screening until the final follow up visit (day 50)
Title
Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal clinical laboratory evaluations
Description
To assess safety and tolerability of GLPG1972 in OA patients
Time Frame
Screening, Days -1, 2, 4, 8, 9, 15, 22, 29, 43 and the final follow up visit (day 50)
Title
Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal physical examination
Description
To assess safety and tolerability of GLPG1972 in OA patients
Time Frame
Screening, days -1, 1, 2, 8, 15, 22, 29, 43 and the final follow up visit (day 50
Title
Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal ECG
Description
To assess safety and tolerability of GLPG1972 in OA patients
Time Frame
Screening, days 1, 2, 3, 4, 8, 15, 22, 29, 43 and the final follow up visit (day 50)
Title
Difference in the number of GLPG1972 treated subjects and placebo subjects with abnormal Holter assessment
Description
To assess safety and tolerability of GLPG1972 in OA patients
Time Frame
Day -1 to days 1 and Day 10 to day 11
Title
The maximum observed plasma concentration of GLPG1972 (Cmax)
Description
To assess PK of GLPG1972 in OA patients
Time Frame
Days 1, 2, 3, 4, 6, 8, 10, 15, 16, 22, 29 and 43
Title
The time (tmax) to reach Cmax of GLPG1972
Description
To assess PK of GLPG1972 in OA patients
Time Frame
Days 1, 2, 3, 4, 6, 8, 10, 15, 16, 22, 29 and 43
Title
The plasma concentration of GLPG1972 24 after the last dose
Description
To assess PK of GLPG1972 in OA patients
Time Frame
Days 1, 2, 3, 4, 6, 8, 10, 15, 16, 22, 29 and 43
Title
The area under the plasma concentration time curve from time 0 until the last quantifieble dose
Description
To assess PK of GLPG1972 in OA patients
Time Frame
Days 1, 2, 3, 4, 6, 8, 10, 15, 16, 22, 29 and 43
Secondary Outcome Measure Information:
Title
Percentage reduction of neo-epitope ARGS vs baseline
Description
To assess PD of GLPE1972 in OA patients
Time Frame
Days 1, 3, 6, 8, 10, 15, 22, 29, 43 and the final follow up visit (day 50)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female subjects of non-childbearing potential, 50-75 years of age on the date of signing the Informed Consent Form (ICF), inclusive extremes. Diagnosis of OA (knee and/or hip) made by their physician based on symptoms, clinical signs and documented historical imaging evidence. A body mass index (BMI) between 18.0 and 34.9 kg/m2, inclusive extremes. Judged to be in age-appropriate good health by the investigator based upon the results of a medical history, physical examination, vital signs and 12-lead ECG, and fasting clinical laboratory profile. Subjects with a stable chronic illness at least 3 months will be accepted subject to the investigator's judgment. Exclusion Criteria: Administration of intraarticular glucocorticoid injections or hyaluronan injections in the last 3 months prior to study screening. Subjects who underwent or are on a waiting list for total hip or knee replacement and any other surgery planned during the study (up to Day 50). Known hypersensitivity to study drug ingredients or a significant allergic reaction to any drug as determined by the investigator, such as anaphylaxis requiring hospitalization. Positive serology for HBsAg or HCV antibody or history of hepatitis from any cause with the exception of hepatitis A. History of or a current immunosuppressive condition. Clinically significant serious, per investigator's discretion, and/or unstable illness in the 3 months before screening Renal function with an estimated creatinine clearance < 60 mL/min based on the Cockcroft-Gault formula. Retesting is allowed once (see Section 5.2). Use of verapamil, diltiazem, amitriptyline, warfarin, acenocoumarol, phenobarbital and phenytoin, within 4 weeks before first study drug administration Consumption of herbal medications that are strong inhibitors and/or inducers of CYPs (e.g., St. John's Wort) and grapefruit/grapefruit products, Seville oranges, or any poppy seed, within 7 days prior to the first study drug administration. History of solid organ or hematopoietic cell transplantation. History of malignancy within the past 5 years. Clinically significant abnormalities detected on 12-lead ECG of either rhythm or conduction (e.g., QTcF ≥ 450 ms for males and QTcF ≥ 470 ms for females, or a known long QT syndrome). Significant blood loss (including blood donation [> 450 mL]), or transfusion of any blood product within 12 weeks prior to screening
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ann Fieuw, MD, MSc
Organizational Affiliation
Galapagos NV
Official's Role
Study Director
Facility Information:
Facility Name
Covance Daytona Beach
City
Daytona Beach
State/Province
Florida
ZIP/Postal Code
32117
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

A Study With GLPG1972 in Osteoarthritis Subjects

We'll reach out to this number within 24 hrs